We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Lunglife Ai Inc | LSE:LLAI | London | Ordinary Share | ORD USD0.0001 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -4.88% | 19.50 | 18.00 | 21.00 | 20.50 | 19.00 | 20.50 | 65,577 | 09:00:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2023 to May 2024
TIDMLLAI
RNS Number : 9096N
LungLife AI, INC
28 September 2023
LungLife AI, Inc.
(the "Company" or "LungLife")
Clinical validation study update
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company's clinical validation study for its LungLB(R) test.
As stated in the Company's half-year report on 8 August 2023, LungLife is currently focussed on preparing data from the clinical validation study for detailed analysis, which was expected to be concluded by the end of September 2023. Due to delays in the provision of data from study sites, full database lock, and the consequent knock-on impact on ability to analyse the data we now expect this to be concluded in Q4 2023.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO Via Walbrook PR David Anderson, CFO Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970 & Joint Broker) Virginia Bull / Cameron MacRitchie / Lydia Zychowska Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202 / +353 (1) Tom Nicholson / Stephen Kane 667 0420 Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 / Marriage 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RESLRMLTMTMTBFJ
(END) Dow Jones Newswires
September 28, 2023 02:00 ET (06:00 GMT)
1 Year Lunglife Ai Chart |
1 Month Lunglife Ai Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
